Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 13, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary Shares of 25 pence each.
- Purchase Date: December 13, 2012.
- Price Range: Highest price paid was 1,371.0 pence per share; lowest price paid was 1,361.5 pence per share.
- Treasury Holdings (Settled): 492,796,327 shares (9.13% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,401,327 shares (10.08% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,904,471,927 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 550,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.08% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure under the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership thresholds.
Investor Verification Checklist
- Verify the total number of shares in issue (4,904,471,927) to calculate personal ownership percentages against Disclosure and Transparency Rules thresholds.
- Confirm the current Treasury share count and its impact on total voting rights (10.08% including unsettled shares).
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.